Delta Electronics’ Board of Directors Approved Proposal to Acquire Shareholdings of ACT Genomics

ACT Genomics is a leading provider of cancer genomics testingservices in Asia and specializes in next-generation sequencing (NGS)technology, supporting a wide range of oncology-related applications, includingearly detection, diagnosis, therapy selection, and post-treatment monitoring.

Delta, a global leader in power management and smart greensolutions, expects to enhance its capabilities in the healthcare sector throughthis transaction by combining ACT Genomics’ expertise in cancer genomics,bioinformatics, and clinical service delivery with its own global footprint.

Dr. Hua-Chien Chen, CEO of ACT Genomics,stated:

“At ACT Genomics, we are committed to making precision medicinemore accessible, helping every cancer patient receive the most effective andaccurate treatment possible. By combining our strengths in oncology, genomics,and bioinformatics, we provide comprehensive cancer genomic testing services.We believe that with Delta’s global scale and technological support, we canrapidly extend our reach and realize our vision of making precision medicinemainstream.”

About ACT Genomics

Founded in 2014, ACT Genomics operates in Taiwan, Hong Kong,  Thailand, and the UK. It is a regional leaderin cancer genomic testing and operates internationally certified clinicallaboratories. Leveraging advanced NGS technology and proprietary reagents, ACTGenomics can analyze over 440 tumor-related genes. It is the first companyoutside the U.S. to receive FDA clearance for a large-panel tumor profilingtest, and its services are included in self-pay medical programs at over 80hospitals in Taiwan. Partners include hospitals, pharmaceutical companies,academic institutions, and insurance firms.

Media Contact
Mu Lee｜Email:mulee@actgenomics.com

For furtherinformation about Delta, please visit: www.deltaww.com

‍